为探究 ponatinib 与 imatinib 对费城染色体阳性急性淋巴细胞白血病（Ph + ALL）患者健康相关生活质量（HRQoL）的影响，研究人员开展 PhALLCON 试验。结果显示，ponatinib 在改善患者 HRQoL 等方面更具优势，这为 Ph + ALL 治疗提供了重要参考。 在血液疾病的世界里 ...

Despite failing to achieve MRD-negativity after induction, patients with Ph+ acute lymphoblastic leukemia treated with ...

2 Patients were recruited into six multicenter phase II studies and were treated with 400 to 600 mg imatinib p.o. daily. Primary resistant disease was considered as lack of hematologic response ...

If you have a certain type of cancer, your doctor may discuss imatinib oral tablets with you. This is a prescription drug that’s used to treat some types of blood cancer and skin cancer.

Imatinib (Gleevec, Novartis, Basel, Switzerland), formerly referred to as STI571, is an inhibitor of specific protein tyrosine kinases that was targeted to the platelet-derived growth factor (PDGF ...

Imatinib is approved by the FDA for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Imatinib potently inhibits a select set of tyrosine kinases at ...

We assessed the efficacy and safety of dasatinib, as compared with imatinib, for the first-line treatment of chronic-phase CML. In a multinational study, 519 patients with newly diagnosed chronic ...

In this ongoing, multinational, phase III study, 536 patients with newly diagnosed chronic-phase CML were randomly assigned 1:1 to receive 400 mg of bosutinib once daily (n = 268) or imatinib (n = 268 ...

Two distinct phase II trials of imatinib (400 to 800 mg daily) in patients with locally advanced or metastatic DFSP were conducted and closed prematurely, one in Europe (European Organisation for ...

Please provide your email address to receive an email when new articles are posted on . Imatinib interruption resulted in shorter median OS. Interruption also appeared linked to rapid progression ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of imatinib as an adjuvant treatment, having considered evidence on the nature of gastrointestinal stromal ...